Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

BACKGROUND: Abiraterone and enzalutamide are currently approved for mCRPC patients. Both drugs have distinct mechanisms of action and may have different toxicity profile. There are limited data comparing the side effects of abiraterone and enzalutamide. We performed a meta-analysis of randomized con...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Raphael B., Debiasi, Marcio, Francini, Edoardo, Nuzzo, Pier V., Velasco, Guillermo De, Maluf, Fernando C., Fay, Andre P., Bellmunt, Joaquim, Choueiri, Toni K., Schutz, Fabio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663621/
https://www.ncbi.nlm.nih.gov/pubmed/29137449
http://dx.doi.org/10.18632/oncotarget.20028

Ejemplares similares

Ejemplares similares